tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.58838/2075-1230-2025-103-6-104-116tiblj-1939Research ArticleОБЗОРЫREVIEWSВозможности фармакогенетического тестирования в лечении туберкулезаPotential of Pharmacogenetic Testing in Tuberculosis TreatmentИвановаД. А.IvanovaD. A.

Иванова Диана Александровна - Д. м. н., ученый секретарь, врач-фтизиатр; врач-терапевт городского клинико-диагностического центра, профессор кафедры фтизиатрии 

107014, г. Москва, ул. Стромынка, д. 10, стр. 1Тел.: +7 (499) 269-14-10

Diana A. Ivanova - Doctor of Medical Sciences, Academic Secretary, Phthisiologist, General Practitioner of City Clinical Diagnostic Center, Professor of Phthisiology Department 

10 Build. 1, Stromynka St., Moscow 107014Phone: +7 (499) 269-14-10

d-ivanova@list.ruНиколенкоН. Ю.NikolenkoN. Yu.

Николенко Николай Юрьевич - К. фарм. н., научный сотрудник научно-клинического отдела

107014, г. Москва, ул. Стромынка, д. 10, стр. 1Тел.: +7 (499) 269-14-10

Nikolay Yu. Nikolenko - Candidate of Pharmacological Sciences, Researcher of Research Clinical Department

10 Build. 1, Stromynka St., Moscow 107014Phone: +7 (499) 269-14-10

nynikolenko@me.comКудлайД. А.GalkinaK. Yu.

Кудлай Дмитрий Анатольевич - Член-корреспондент РАН, д. м. н., профессор кафедры фармакологии Института фармации; ведущий научный сотрудник лаборатории персонализированной медициныи молекулярной иммунологии № 71 ФГБУ «ГНЦ Институт иммунологии» ФМБА России; профессор кафедры фармакогнозии и промышленной фармации факультета фундаментальной медицины ФГБОУ ВО МГУ имени М.В. Ломоносова

119991, г. Москва, ул. Трубецкая, д. 8, стр. 2Тел. +7 (499) 248-05-53

Kseniya Yu. Galkina - Candidate of Biological Sciences, Leading Researcher of Department of Laboratory Diagnostics of Tuberculosis and Pathomorphology

10 Build. 1, Stromynka St., Moscow 107014Phone: +7 (499) 269-14-10

D624254@gmail.comГалкинаК. Ю.YurovskayaE. I.

Галкина Ксения Юрьевна - К. б. н., ведущий научный сотрудник отдела проблем лабораторной диагностики туберкулеза и патоморфологии

107014, г. Москва, ул. Стромынка, д. 10, стр. 1Тел.: +7 (499) 269-14-10

Ekaterina I. Yurovskaya - Phthisiologist of Pulmonary Tuberculosis Department no. 6 of Clinic no. 2

10 Build. 1, Stromynka St., Moscow 107014Phone: +7 (499) 269-14-10

ksyu.galkina.79@list.ruЮровскаяЕ. И.MitrofanovaYu. Yu.

Юровская Екатерина Игоревна - Врач-фтизиатр туберкулезного легочного отделения № 6 Клиники № 2

107014, г. Москва, ул. Стромынка, д. 10, стр. 1Тел.: +7 (499) 269-14-10

Yulia Yu. Mitrofanova - Researcher of Research Clinical Department

10 Build. 1, Stromynka St., Moscow 107014Phone: +7 (499) 269-14-10

dr.the_end_tb@mail.ruМитрофановаЮ. Ю.KudlayD. A.

Митрофанова Юлия Юрьевна - Научный сотрудник научно-клинического отдела

107014, г. Москва, ул. Стромынка, д. 10, стр. 1Тел.: +7 (499) 269-14-10

Dmitry A. Kudlay - Correspondent Member of RAS, Doctor of Medical Sciences, Professor of Pharmacology Department of Pharmacy Institute, Leading Researcher of Laboratory of Personalized Medicine and Molecular Immunology no. 71, Immunology Research Institute by the Russian Federal Medical Biological Agency, Professor of Department of Pharmacognosy and Industrial Pharmacy, Fundamental Medicine Faculty, Lomonosov Moscow State University

8 Bd. 2, Trubetskaya St., Moscow, 119991Phone: +7 (499) 248-05-53

yuyumit@yandex.ruГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияMoscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health; Russian Medical Academy of On-going Professional Education, Russian Ministry of HealthRussian FederationГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»РоссияMoscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of HealthRussian FederationФГАОУ ВО «Первый МГМУ им. И. М. Сеченова (Сеченовский Университет)» МЗ РФ; ФГБОУ ВПО «Московский государственный университет имени М.В. Ломоносова»; ФГБУ «ГНЦ Институт иммунологии» ФМБА РоссииРоссияMoscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of HealthRussian FederationГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), Russian Ministry of Health; Lomonosov Moscow State University; Immunology Research Institute by the Russian Federal Medical Biological AgencyRussian Federation2025100120261036104116Copyright © Иванова Д.А., Николенко Н.Ю., Кудлай Д.А., Галкина К.Ю., Юровская Е.И., Митрофанова Ю.Ю., 20262026Иванова Д.А., Николенко Н.Ю., Кудлай Д.А., Галкина К.Ю., Юровская Е.И., Митрофанова Ю.Ю.Ivanova D.A., Nikolenko N.Y., Galkina K.Y., Yurovskaya E.I., Mitrofanova Y.Y., Kudlay D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1939

Фармакогенетическое тестирование – наиболее перспективный инструмент персонализированной медицины, направленный на повышение эффективности и безопасности лечения, особенно у сложных коморбидных пациентов. Проведен анализ 122 публикаций, посвященных теоретическим и прикладным аспектам применения фармакогенетического тестирования при лечении больных туберкулезом. Рассмотрена роль генетических полиморфизмов в ответе на лечение, представлены данные о белках, участвующих в процессах фармакокинетики и фармакодинамики основных противотуберкулезных препаратов, и кодирующих эти белки генах. Проанализирован перечень наиболее значимых маркеров, связанных с риском нежелательных реакций при лечении лекарственно-чувствительного и лекарственно-устойчивого туберкулеза, охарактеризованы перспективы их применения в клинической практике. В списке литературы отражены 56 ключевых публикаций, на которые имеются ссылки в тексте. 

Pharmacogenetic testing is the most promising tool in personalized medicine aimed at enhancing effectiveness and safety of treatment, especially in complicated cases with comorbidities. The review analyzes 122 publications devoted to theoretical and applied aspects of pharmacogenetic testing in the treatment of tuberculosis patients. It considers the role of genetic polymorphisms in the response to treatment, and presents data on proteins involved in pharmacokinetics and pharmacodynamics of main anti-tuberculosis drugs and the genes encoding these proteins. The review analyzes the list of the most significant markers associated with the risk of adverse reactions during treatment of drug-sensitive and drug-resistant tuberculosis, and it characterizes prospects for their use in clinical practice. The list of references contains 56 key publications cited in the text. 

фармакогенетическое тестированиелечение туберкулезапротивотуберкулезные препаратыфармакогенетический маркергенетический полиморфизмpharmacogenetic testingtuberculosis treatmentanti-tuberculosis drugspharmacogenetic markergenetic polymorphismReferencesАлыменко М.А., Валиев Р.Ш., Валиев Н.Р., Трагира И.Н., Полоников А.В., Балобанова Н.П., Батищев А.В., Коломиец В.М., Маль Г.С., Волкова С.Н., Козлов В.В., Сусликова Е.И., Попова Е.В. Влияние полиморфизма гена МDR1 (ABCB1) на риск развития гепатотоксических реакций у больных туберкулезом легких // Антибиотики и Химиотерапия. – 2023. – Т. 68, № 7-8. – С. 62-69. https://doi.org/10.37489/0235-2990-2023-68-7-8-62-69Alymenko М.А., Valiev R.S., Valiev N.R., Tragira I.N., Polonikov А.V., Balobanova N.Р., Batishchev A.V., Kolomiets V.М., Mal G.S., Volkova S.N., Kozlov V.V., Suslikova E.I., Popova E.V. The effect of polymorphism of the MDR1 (ABCB1) gene on the risk of hepatotoxic reactions in patients with pulmonary tuberculosis. Antibiotics and Chemotherapy, 2023, vol. 68, no. 7-8, pp. 62-69. (In Russ.) https://doi.org/10.37489/0235-2990-2023-68-7-8-62-69Захаров А.В., Еремеев В.В., Чумоватов Н.В., Полякова А.С., Шепелькова Г.С., Комиссарова О.Г., Романов В.В., Эргешов А.Э. Клинико-генетические ассоциации полиморфных аллелей гена CYP3A4 у больных туберкулезом легких с лекарственной устойчивостью возбудителя // Вестник ЦНИИТ. – 2024. – Т. 8, № 4. – С. 17-30. https://doi.org/10.57014/2587-6678-2024-8-4-17-30Zakharov A.V., Yeremeev V.V., Chumovatov N.V., Polyakova A.S., Shepelkova G.S., Komissarova O.G., Romanov V.V., Ergeshov A.E. Clinical and genetic associations of polymorphic alleles of the CYP3A4 gene in drug-resistant pulmonary TB. Vestnik TSNIIT, 2024, vol. 8, no. 4, pp. 17-30. (In Russ.) https://doi.org/10.57014/2587-6678-2024-8-4-17-30Иванова Д.А., Галкина К.Ю., Борисов С.Е., Сафонова С.Г., Кудлай Д.А. Фармакогенетические методы в оценке риска гепатотоксических реакций при лечении впервые выявленных больных туберкулезом // Туберкулез и социально значимые заболевания. – 2018. – Т. 6, № 3. – С. 43-48.Ivanova D.A., Galkina K.Yu., Borisov S.E., Safonova S.G., Kudlay D.A. Pharmacogenetic methods in assessing the risk of hepatotoxic reactions in the treatment of new tuberculosis patients. Tuberculosis and Socially Significant Diseases, 2018, vol. 6, no. 3, pp. 43-48. (In Russ.)Иванова Д.А., Юровская Е.И., Галкина К.Ю. Фармакогенетические маркеры в лечении больных туберкулезом с множественной лекарственной устойчивостью возбудителя // Фармакогенетика и фармакогеномика. – 2025. – № 2. – С. 23-29. https://doi.org/10.37489/2588-0527-2025-2-23-29Ivanova D.A., Yurovskaya E.I., Galkina K.Yu. Pharmacogenetic markers in the treatment of patients with multidrug-resistant tuberculosis. Pharmacogenetics and Pharmacogenomics, 2025, no. 2, pp. 23-29. (In Russ.) https://doi.org/10.37489/2588-0527-2025-2-23-29Краснова Н.М., Евдокимова Н.Е., Егорова А.А., Филиппова О.И., Алексеева Е.А., Рудых З.А., Чертовских Я.В., Венгеровский А.И., Кравченко А.Ф., Сычев Д.А. Влияние типа ацетилирования на частоту гепатотоксичности изониазида у пациентов с впервые выявленным туберкулезом органов дыхания // Антибиотики и Химиотерапия. – 2020. – Т. 65, № 7-8. – С. 31-36. https://doi.org/10.37489/0235-2990-2020-65-7-8-31-36Krasnova N.M., Evdokimova N.E., Egorova A.A., Filippova O.I., Alekseeva E.A., Rudykh Z.A., Chertovskykh Y.V., Vengerovskii A.I., Kravchenko A.F., Sychev D.A. Influence of the acetylation type on the incidence of isoniazid-induced hepatotoxicity in patients with newly diagnosed pulmonary tuberculosis. Antibiotics and Chemotherapy, 2020, vol. 65, no. 7-8, pp. 31-36. (In Russ.) https://doi.org/10.37489/0235-2990-2020-65-7-8-31-36Краснова Н.М., Николаев В.М., Татаринова О.В., Прокопьев Е.С., Венгеровский А.И., Сычев Д.А. Зависимость режима дозирования от скорости ацетилирования изониазида у пациентов с впервые выявленным туберкулезом легких // Экспериментальная и клиническая фармакология. – 2024. – Т. 87, № 8. – С. 20-25. https://doi.org/10.30906/0869-2092-2024-87-8-20-25Krasnova N.M., Nikolaev V.M., Tatarinova O.V., Prokopyev E.S., Vengerovskii A.I., Sychev D.A. Dependence of the dosing regimen on the rate of isoniazid acetylation in patients with newly diagnosed pulmonary tuberculosis. Eksperimentalnaya i Klinicheskaya Farmakologiya, 2024, vol. 87, no. 8, pp. 20-25. (In Russ.) https://doi.org/10.30906/0869-2092-2024-87-8-20-25Можокина Г.Н., Казаков А.В., Елистратова Н.А., Попов С.А. Ферменты биотрансформации ксенобиотиков и персонификация режимов лечения больных туберкулезом // Туберкулез и болезни легких. – 2016. – Т. 94, № 4. – С. 6-12. https://doi.org/10.21292/2075-1230-2016-94-4-6-12Mozhokina G.N., Kazakov A.V., Elistratova N.A., Popov S.A. Biotransformation enzymes for xenobiotics and personalization of treatment regimens for tuberculosis patients. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 4, pp. 6-12. (In Russ.) https://doi.org/10.21292/2075-1230-2016-94-4-6-12Прикладная фармакогенетика: Монография / под ред. Д.А. Сычева. – Тверь: ООО «Издательство «Триада», 2021.Prikladnaya farmakogenetika: Monografiya. [Applied Pharmacogenetics. Monograph]. D.A Sychev, eds., Tver, OOO Izdatelstvo Triada Publ., 2021.Степанова Н.А. Персонализированные подходы к повышению эффективности и безопасности фармакотерапии туберкулеза органов дыхания: автореф. дисс. ...докт. мед. наук / Н. А. Степанова. – Москва, 2022. URL: https://critub.ru/wp-content/uploads/AvtoreferatStepanovaNA-na-sajt.pdf [Дата обращения 27.09.2025].Stepanova N.A. Personalizirovannyye podkhody k povysheniyu effektivnosti i bezopasnosti farmakoterapii tuberkuleza organov dykhaniya. Avtoref. diss. dokt. med. nauk. [Personalized approaches to improving the effectiveness and safety of pharmacotherapy of respiratory tuberculosis. Synopsis of Doct. Diss.]. Moscow, 2022. Available: https://critub.ru/wp-content/uploads/AvtoreferatStepanovaNA-na-sajt.pdf Accessed September 27, 2025Тюлькова Т. Е., Ткачук А. П., Акмалова К. А., Абдуллаев Ш. П., Мирзаев К. Б., Сычев Д. А., Мануйлов В. А. Генетический полиморфизм, влияющий на метаболизм противотуберкулезных препаратов // Фармакогенетика и фармакогеномика. – 2024. – № 2. – С. 37-45. https://doi.org/ 10.37489/2588-527-2024-2-37-45Tyulkova T.E., Tkachuk A.P., Akmalova K.A., Abdullaev Sh.P., Mirzaev K.B., Sychev D.A., Manuylov V.A. Genetic polymorphisms affect the metabolism of antituberculosis drugs. Pharmacogenetics and Pharmacogenomics, 2024, no. 2, pp. 37-45. (In Russ.) https://doi.org/10.37489/2588-0527-2024-2-37-45Юнусбаева М.М., Бородина Л.Я., Билалов Ф.С., Шарипов Р.А., Юнусбаев Б.Б. Исследование влияния полиморфизма генов CYP3A5, CYP2B6 и NAT2 на эффективность лечения туберкулеза с множественной лекарственной устойчивостью // Фармакогенетика и фармакогеномика. – 2020. – № 2. – С. 26-27. https://doi.org/10.37489/2588-0527-2020-2-26-27Yunusbaeva M.M., Borodina L.Ya., Bilalov F.S., Sharipov R.A., Yunusbaev B.B. A study of the influence of CYP3A5, CYP2B6 and NAT2 gene polymorphism on the effectiveness of treatment for multidrug-resistant tuberculosis Pharmacogenetics and Pharmacogenomics, 2020, no. 2, pp. 26-27. (In Russ.) https://doi.org/10.37489/2588-0527-2020-2-26-27Ahmad J., Dellinger A., Nicoletti P., Barnhart H.X., Ghabril M., Fontana R.J., et al. Clinical and HLA associations of fluoroquinolone-induced liver injury: results from the drug-induced liver injury network // The American Journal of Gastroenterology. – 2025. – № 10. – Р. 14309. https://doi.org/10.14309/ajg.0000000000003457Ahmad J., Dellinger A., Nicoletti P., Barnhart H.X., Ghabril M., Fontana R.J. et al. Clinical and HLA associations of fluoroquinolone-induced liver injury: results from the drug-induced liver injury network. The American Journal of Gastroenterology, 2025, no. 10, pp. 14309. https://doi.org/10.14309/ajg.0000000000003457Ahmed S., Zhou Z., Zhou J., Chen S.Q. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine // Genomics, Proteomics & Bioinformatics. – 2016. – Vol. 14, №. 5. – P. 298-313. https://doi.org/10.1016/j.gpb.2016.03.008.Ahmed S., Zhou Z., Zhou J., Chen S.Q. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics, Proteomics & Bioinformatics, 2016, vol. 14, no. 5, pp. 298-313. https://doi.org/10.1016/j.gpb.2016.03.008.Allegra S., Di Paolo A., Cusato J., Fatiguso G., Arrigoni E., Danesi R., Corcione S., D'Avolio A. Different underlying mechanism might explain the absence of a significant difference in area under the concentration-time curve of linezolid for different ABCB1 genotypes // Therapeutic Drug Monitoring. – 2019. – Vol. 41, № 2. – P. 254-255. https://doi.org/10.1097/FTD.0000000000000Allegra S., Di Paolo A., Cusato J., Fatiguso G., Arrigoni E., Danesi R., Corcione S., D'Avolio A. Different underlying mechanism might explain the absence of a significant difference in area under the concentration-time curve of linezolid for different ABCB1 genotypes. Therapeutic Drug Monitoring, 2019, vol. 41, no. 2, pp. 254-255. https://doi.org/10.1097/FTD.0000000000000596Araujo-Mariz C., Militão de Albuquerque M.F.P., Lopes E.P., Ximenes R.A.A., Lacerda H.R., Miranda-Filho D.B., Lustosa-Martins B.B., Pastor A.F.P., Acioli-Santos B. Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil // Annals of Hepatology. – 2020. – Vol. 19, № 2. – Р. 153-160. https://doi.org/10.1016/j.aohep.2019.09.008Araujo-Mariz C., Militão de Albuquerque M.F.P., Lopes E.P., Ximenes R.A.A., Lacerda H.R., Miranda-Filho D.B., Lustosa-Martins B.B., Pastor A.F.P., Acioli-Santos B. Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil. Annals of Hepatology, 2020, vol. 19, no. 2, pp. 153-160. https:// doi.org/10.1016/j.aohep.2019.09.008Azuma J., Ohno M., Kubota R., Yokota S., Nagai T., Tsuyuguchi K., Okuda Y., Takashima T., Kamimura S., Fujio Y., Kawase I. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy // European Journal of Clinical Pharmacology. – 2013. – Vol. 69, № 5. – Р. 1091-1101. https://doi.org/10.1007/s00228-012-1429-9Azuma J., Ohno M., Kubota R., Yokota S., Nagai T., Tsuyuguchi K., Okuda Y., Takashima T., Kamimura S., Fujio Y., Kawase I. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. European Journal of Clinical Pharmacology, 2013, vol. 69, no. 5, pp. 1091-1101. https:// doi.org/10.1007/s00228-012-1429-9Barliana M.I., Afifah N.N., Yunivita V., Ruslami R. Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicity // Frontiers in Genetics. – 2023. – № 14. –Р. 1118102. https://doi.org/10.3389/fgene.2023.1118102Barliana M.I., Afifah N.N., Yunivita V., Ruslami R. Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicity. Frontiers in Genetics, 2023, no. 14, pp. 1118102. https://doi.org/10.3389/fgene.2023.1118102Cai Y., Yi J., Zhou C., Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis // PLoS One. – 2012. – Vol. 7, № 10. – Р. e47769. https://doi.org/10.1371/journal.pone.0047769Cai Y., Yi J., Zhou C., Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One, 2012, vol. 7, no. 10, pp. e47769. https://doi.org/10.1371/journal.pone.0047769Cheli S., Fusi M., De Silvestri A., Bonini I., Clementi E., Cattaneo D., Montrasio C., Baldelli S. In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5 // Biomedicine & Pharmacotherapy. – 2021. – № 139. – Р. 111631. https://doi.org/10.1016/j.biopha.2021.111631Cheli S., Fusi M., De Silvestri A., Bonini I., Clementi E., Cattaneo D., Montrasio C., Baldelli S. In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5. Biomedicine & Pharmacotherapy, 2021, no. 139, pp. 111631. https://doi.org/10.1016/j.biopha.2021.111631Clinical Pharmacogenomics (ClinPgx). Available at: https://www.clinpgx.org/ [Accessed 30.09.2025].Clinical Pharmacogenomics (ClinPgx). Available: https://www.clinpgx.org/ Accessed September 30, 2025Fernandes D.C., Santos N.P., Moraes M.R., Braga A.C., Silva C.A., Ribeiro-dos-Santos A., Santos S. Association of the CYP2B6 gene with anti-tuberculosis drug-induced hepatotoxicity in a Brazilian Amazon population // International journal of infectious diseases. – 2015. – № 33. – P. 28-31. https://doi.org/10.1016/j.ijid.2014.04.011Fernandes D.C., Santos N.P., Moraes M.R., Braga A.C., Silva C.A., Ribeiro-dos-Santos A., Santos S. Association of the CYP2B6 gene with anti-tuberculosis drug-induced hepatotoxicity in a Brazilian Amazon population. International Journal of Infectious Diseases, 2015, no. 33, pp. 28-31. https://doi.org/10.1016/j.ijid.2014.04.011Garrabou G., Soriano À., Pinós T., Casanova-Mollà J., Pacheu-Grau D., Morén C., et al. Influence of Mitochondrial Genetics on the Mitochondrial Toxicity of Linezolid in Blood Cells and Skin Nerve Fibers // Antimicrobial Agents and Chemotherapy. – 2017. – Vol. 61, № 9. – Р. e00542-17. https://doi.org/10.1128/AAC.00542-17Garrabou G., Soriano À., Pinós T., Casanova-Mollà J., Pacheu-Grau D., Morén C. et al. Influence of mitochondrial genetics on the mitochondrial toxicity of linezolid in blood cells and skin nerve fibers. Antimicrobial Agents and Chemotherapy, 2017, vol. 61, no. 9, pp. e00542-17. https://doi.org/10.1128/AAC.00542-17Haas D.W., Abdelwahab M.T., van Beek S.W., Baker P., Maartens G., Bradford Y., et al. Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa // The Journal of Infectious Diseases. – 2022. – Vol. 226, № 1. – P. 147-156. https://doi.org/10.1093/infdis/jiac024Haas D.W., Abdelwahab M.T., van Beek S.W., Baker P., Maartens G., Bradford Y. et al. Pharmacogenetics of between-individual variability in plasma clearance of bedaquiline and clofazimine in South Africa. The Journal of Infectious Diseases, 2022, vol. 226, no. 1, pp. 147-156. https://doi.org/10.1093/infdis/jiac024Headriawan A., Pramono A.A., Sukadi A., et al. NAT2 Gene rs1041983 is associated with anti-tuberculosis drug induced hepatotoxicity among pediatric tuberculosis in Bandung, Indonesia // The Application of Clinical Genetics. – 2021. – № 14. – P. 297-303. https://doi.org/10.2147/TACG.S303668Headriawan A., Pramono A.A., Sukadi A. et al. NAT2 Gene rs1041983 is associated with anti-tuberculosis drug induced hepatotoxicity among pediatric tuberculosis in Bandung, Indonesia. The Application of Clinical Genetics, 2021, no. 14, pp. 297-303. https://doi.org/10.2147/TACG.S303668Hoa P.Q., Kim H.K., Jang T.W., Seo H., Oh J.Y., Kim H.C., et al. Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposure // International Journal of Antimicrobial Agents. – 2024. – Vol. 63, № 2. – Р. 107034. https://doi.org/10.1016/j.ijantimicag.2023.107034Hoa P.Q., Kim H.K., Jang T.W., Seo H., Oh J.Y., Kim H.C. et al. Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposure. International Journal of Antimicrobial Agents, 2024, vol. 63, no. 2, pp. 107034. https://doi.org/10.1016/j.ijantimicag.2023.107034Hussain Z., Zhu J., Ma X. Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug // Drug Metabolism and Disposition: the Biological Fate of Chemicals. – 2021. – Vol. 49, № 8. – P. 679-682. https://doi.org/10.1124/dmd.121.000389Hussain Z., Zhu J., Ma X. Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021, vol. 49, no. 8, pp. 679-682. https://doi.org/10.1124/dmd.121.000389Jiang M., Yang J., Yang L., Wang L, Wang T., Han S. et al. An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese // iScience. – 2023. – Vol. 26, № 8. – Р. е107391. https://doi.org/10.1016/j.isci.2023.107391Jiang M., Yang J., Yang L., Wang L, Wang T., Han S. et al. An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese. iScience, 2023, vol. 26, no. 8, pp. е107391. https://doi.org/10.1016/j.isci.2023.107391Kivrane A., Ulanova V., Grinberga S., Sevostjanovs E., Viksna A., Ozere I., Bogdanova I., Zolovs M., Ranka R. Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective // Pharmaceutics. – 2024. – Vol. 16, № 3. – Р. 388. https://doi.org/10.3390/pharmaceutics16030388Kivrane A., Ulanova V., Grinberga S., Sevostjanovs E., Viksna A., Ozere I., Bogdanova I., Zolovs M., Ranka R. Exploring variability in rifampicin plasma exposure and development of anti-tuberculosis drug-induced liver injury among patients with pulmonary tuberculosis from the pharmacogenetic perspective. Pharmaceutics, 2024, vol. 16, no. 3, pp. 388. https://doi.org/10.3390/pharmaceutics16030388Lopez-Medina A.I., Campos-Staffico A.M., Chahal C.A., Volkers I., Jacoby J.P., Berenfeld O., Luzum J.A. Genetic risk factors for drug-induced long QT syndrome: findings from a large real-world case-control study // Pharmacogenomics. – 2024. – Vol. 25, №3. – Р.117-131. https://doi.org/10.2217/pgs-2023-0229Lopez-Medina A.I., Campos-Staffico A.M., Chahal C.A., Volkers I., Jacoby J.P., Berenfeld O., Luzum J.A. Genetic risk factors for drug-induced long QT syndrome: findings from a large real-world case-control study. Pharmacogenomics, 2024, vol. 25, no. 3, pp. 117-131. https://doi.org/ 10.2217/pgs-2023-0229Mackay E., Platt G., Peloquin C.A., Brooks M.B., Coit J.M., Velásquez G.E., et al. Impact of pharmacogenetics on pharmacokinetics of first-line antituberculosis drugs in the HIRIF Trial // The Journal of Infectious Diseases. – 2025. – Vol. 232, № 2. – P. 258-265. https://doi.org/10.1093/infdis/jiaf195Mackay E., Platt G., Peloquin C.A., Brooks M.B., Coit J.M., Velásquez G.E. et al. Impact of pharmacogenetics on pharmacokinetics of first-line antituberculosis drugs in the HIRIF Trial. The Journal of Infectious Diseases, 2025, vol. 232, no. 2, pp. 258-265. https://doi.org/10.1093/infdis/jiaf195Mahajan R., Tyagi A.K. Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis // BMC Genomics Data. – 2024. – Vol. 25, № 1. – Р. 103. https://doi.org/10.1186/s12863-024-01286-yMahajan R., Tyagi A.K. Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis. BMC Genomics Data, 2024, vol. 25, no. 1, pp. 103. https://doi.org/10.1186/s12863-024-01286-yManca A., Calcagno A., D'Avolio A., Cusato J. Pharmacogenetics of first-line antitubercular drugs: an update // Therapeutic Drug Monitoring. – 2025, № 2. – Online ahead of print. https://doi.org/10.1097/FTD.0000000000001378Manca A., Calcagno A., D'Avolio A., Cusato J. Pharmacogenetics of first-line antitubercular drugs: an update. Therapeutic Drug Monitoring, 2025, no. 2. Online ahead of print. https://doi.org/10.1097/FTD.0000000000001378McDermott J.H., Wolf J., Hoshitsuki K., Huddart R., Caudle K.E., Whirl-Carrillo M., et al. Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype // Clin Pharmacol Ther. – 2022. –Vol. 111, № 2. – Р. 366-372. https://doi.org/10.1002/cpt.2309McDermott J.H., Wolf J., Hoshitsuki K., Huddart R., Caudle K.E., Whirl-Carrillo M. et al. clinical pharmacogenetics implementation consortium guideline for the use of aminoglycosides based on MT-RNR1 genotype. Clin. Pharmacol. Ther., 2022, vol. 111, no. 2, pp. 366-372. https://doi.org/10.1002/cpt.2309Naidoo A., Ramsuran V., Chirehwa M., Denti P., McIlleron H., Naidoo K., et al. Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis // Pharmacogenomics. – 2018. – Vol. 19, № 1. – Р. 17-29. https://doi.org/10.2217/pgs-2017-0144Naidoo A., Ramsuran V., Chirehwa M., Denti P., McIlleron H., Naidoo K. et al. Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Pharmacogenomics, 2018, vol. 19, no. 1, pp. 17-29. https://doi.org/10.2217/pgs-2017-0144Oelofse C., Ndong Sima C.A.A., Möller M., Uren C. Pharmacogenetics as part of recommended precision medicine for tuberculosis treatment in African populations: Could it be a reality? // Clinical and Translational Science. – 2023. – Vol. 16, № 7. – P. 1101-1112. https://doi.org/10.1111/cts.13520Oelofse C., Ndong Sima C.A.A., Möller M., Uren C. Pharmacogenetics as part of recommended precision medicine for tuberculosis treatment in African populations: Could it be a reality? Clinical and Translational Science, 2023, vol. 16, no. 7, pp. 1101-1112. https://doi.org/10.1111/cts.13520Pasipanodya J.G., Srivastava S., Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy // Clinical Infectious Diseases. – 2012. – Vol. 55, № 2. – Р. 169-177. https://doi.org/10.1093/cid/cis353Pasipanodya J.G., Srivastava S., Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clinical Infection Diseases, 2012, vol. 55, no. 2, pp. 169-177. https://doi.org/ 10.1093/cid/cis353Peng W., Zhao Z.Z., Jiao L., Wu T., Chen H., Zhang C.Y., et al. Prospective study of ALDH1A1 gene polymorphisms associated with antituberculosis drug-induced liver injury in western Chinese Han population // Microbiol Immunol. – 2021. – Vol. 65, № 4. – Р. 143-153. https://doi.org/10.1111/1348-0421.12877Peng W., Zhao Z.Z., Jiao L., Wu T., Chen H., Zhang C.Y. et al. Prospective study of ALDH1A1 gene polymorphisms associated with antituberculosis drug-induced liver injury in western Chinese Han population. Microbiol. Immunol., 2021, vol. 65, no. 4, pp. 143-153. https://doi.org/ 10.1111/1348-0421.12877Petros Z., Lee M.M., Takahashi A., Zhang Y., Yimer G., Habtewold A., Amogne W., Aderaye G., Schuppe-Koistinen I., Mushiroda T., Makonnen E., Kubo M., Aklillu E. Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity // BMC Genomics. – 2016. – Vol. 17, № 1. – Р. 755. https://doi.org/10.1186/s12864-016-3078-3Petros Z., Lee M.M., Takahashi A., Zhang Y., Yimer G., Habtewold A., Amogne W., Aderaye G., Schuppe-Koistinen I., Mushiroda T., Makonnen E., Kubo M., Aklillu E. Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity. BMC Genomics, 2016, vol. 17, no. 1, pp. 755. https://doi.org/10.1186/s12864-016-3078-3Rens N.E., Uyl-de Groot C.A., Goldhaber-Fiebert J.D., Croda J., Andrews J.R. Cost-effectiveness of a pharmacogenomic test for stratified isoniazid dosing in treatment of active tuberculosis // Clinical Infectious Diseases. – 2020. – № 71. – Р. 3136-3143. https://doi.org/10.1093/cid/ciz1212Rens N.E., Uyl-de Groot C.A., Goldhaber-Fiebert J.D., Croda J., Andrews J.R. Cost-effectiveness of a pharmacogenomic test for stratified isoniazid dosing in treatment of active tuberculosis. Clinical Infection Diseases, 2020, no. 71, pp. 3136-3143. https://doi.org/10.1093/cid/ciz1212Richardson M., Kirkham J., Dwan K., Sloan D.J., Davies G., Jorgensen A.L. NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis // International Journal of Tuberculosis and Lung Disease. – 2019. – Vol. 23, № 3. – Р. 293-305. https://doi.org/10.5588/ijtld.18.0324Richardson M., Kirkham J., Dwan K., Sloan D.J., Davies G., Jorgensen A.L. NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. International Journal Tuberculosis and Lung Disease, 2019, vol. 23, no. 3, pp. 293-305. https://doi.org/10.5588/ijtld.18.0324Santoso S.B., Pribadi P., Irham L.M. Isoniazid-induced liver injury risk level in different variants of N-acetyltransferase 2 (NAT2) polymorphisms: a literature review // Pharmacia. – 2023. – Vol.70, № 4. – Р. 973-981. https://doi.org/10.3897/pharmacia.70.e109869Santoso S.B., Pribadi P., Irham L.M. Isoniazid-induced liver injury risk level in different variants of N-acetyltransferase 2 (NAT2) polymorphisms: a literature review. Pharmacia, 2023, vol. 70, no. 4, pp. 973-981. https://doi.org/10.3897/pharmacia.70.e109869Schiuma M., Dinegro S., Battini V., Torre A., Covizzi A., Civati A., et al. NAT2 acetylation status predicts hepatotoxicity during antituberculosis therapy: cumulative risk analysis of a multiethnic cohort // International Journal of Molecular Sciences. – 2025.– Vol. 26, № 8. – Р. 3881. https://doi.org/10.3390/ijms26083881Schiuma M., Dinegro S., Battini V., Torre A., Covizzi A., Civati A. et al. NAT2 acetylation status predicts hepatotoxicity during antituberculosis therapy: cumulative risk analysis of a multiethnic cohort. International Journal of Molecular Sciences, 2025, vol. 26, no. 8, pp. 3881. https://doi.org/10.3390/ijms26083881Sherwin K.B.S, de Kock L., Diacon A.H., Werely C.J., Xia H., Rosenkranz B., van der Merwe L., Donald P.R. N-Acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis // Antimicrob Agents Chemotherю – 2015. – Vol. 59, № 7. –Р. 4129-4138. https://doi.org/10.1128/aac.04049-14Sherwin K.B.S, de Kock L., Diacon A.H., Werely C.J., Xia H., Rosenkranz B., van der Merwe L., Donald P.R. N-Acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. Antimicrob. Agents Chemother., 2015, vol. 59, no. 7, pp. 4129-4138. https://doi.org/10.1128/aac.04049-14Sileshi T., Makonnen E., Telele N.F., Barclay V., Zumla A., Aklillu E. Variability in plasma rifampicin concentrations and role of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis // Infect Dis (Lond). – 2024. – Vol. 56, № 4. – P. 308-319. https://doi.org/10.1080/23744235.2024.2309348Sileshi T., Makonnen E., Telele N.F., Barclay V., Zumla A., Aklillu E. Variability in plasma rifampicin concentrations and role of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis. Infect. Dis. (Lond.), 2024, vol. 56, no. 4, pp. 308-319. https://doi.org/10.1080/23744235.2024.2309348Spahn C., Toda N., Groat B., Aimer O., Rogers S., Oni-Orisan A., Monte A., Hakooz N. and the Pharmacogenomics Global Research Network Publications Committee. Transforming pharmacovigilance with pharmacogenomics: toward personalized risk management // Clinical Pharmacology & Therapeutics. – 2025. – Vol. 18, № 6. – Р. 1286-1296. https://doi.org/10.1002/cpt.70095.Spahn C., Toda N., Groat B., Aimer O., Rogers S., Oni-Orisan A., Monte A., Hakooz N. and the Pharmacogenomics Global Research Network Publications Committee. Transforming pharmacovigilance with pharmacogenomics: toward personalized risk management. Clinical Pharmacology & Therapeutics, 2025, vol. 18, no. 6, pp. 1286-1296. https://doi.org/10.1002/cpt.70095.Sundell J., Bienvenu E., Birgersson S., Äbelö A., Ashton M. Population pharmacokinetics and pharmacogenetics of ethambutol in adult patients coinfected with tuberculosis and HIV // Antimicrob Agents Chemother. – 2020. – Vol. 64, №2. – Р. e01583-19. https://doi.org/10.1128/AAC.01583-19Sundell J., Bienvenu E., Birgersson S., Äbelö A., Ashton M. Population pharmacokinetics and pharmacogenetics of ethambutol in adult patients coinfected with tuberculosis and HIV. Antimicrob. Agents Chemother., 2020, vol. 64, no. 2, pp. e01583-19. https://doi.org/10.1128/AAC.01583-19Tarazjani A.D., Jouabadi S.M., Jouabadi S.M., Naderi E., Sturkenboom M., Ahmadizar F. Genetic polymorphism and risk of anti-tuberculosis drug-induced liver injury (AT-DILI): a systematic review and meta-analysis. 2025. Available at: https://www.medrxiv.org/collection/pharmacology-andtherapeutics?page=2 [Accessed 21.11.2025].Tarazjani A.D., Jouabadi S.M., Jouabadi S.M., Naderi E., Sturkenboom M., Ahmadizar F. Genetic polymorphism and risk of anti-tuberculosis drug-induced liver injury (AT-DILI): a systematic review and meta-analysis. 2025. Available: https://www.medrxiv.org/collection/pharmacology-andtherapeutics?page=2 Accessed November 21, 2025Ulanova V., Kivrane A., Viksna A., Pahirko L., Freimane L., Sadovska D., et al. Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships // Front Pharmacol. – 2024. – № 15. – Р. 1332752. https://doi.org/10.3389/fphar.2024.1332752.Ulanova V., Kivrane A., Viksna A., Pahirko L., Freimane L., Sadovska D. et al. Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships. Front. Pharmacol., 2024, no. 15, pp. 1332752. https://doi.org/10.3389/fphar.2024.1332752.Verma R., da Silva K.E., Rockwood N., Wasmann R.E., Yende N., Song T., Kim E., Denti P., Wilkinson R.J., Andrews J.R. A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing //American Journal of Respiratory and Critical Care Medicine. – 2024. – Vol. 209, № 12. – Р. 1486-1496. https://doi.org/10.1164/rccm.202309-1583OC.Verma R., da Silva K.E., Rockwood N., Wasmann R.E., Yende N., Song T., Kim E., Denti P., Wilkinson R.J., Andrews J.R. A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing. American Journal of Respiratory and Critical Care Medicine, 2024, vol. 209, no. 12, pp. 1486-1496. https://doi.org/10.1164/rccm.202309-1583OC.VigiAccess. Available at: https://www.vigiaccess.org/ [Accessed 21.11.2025].VigiAccess. Available: https://www.vigiaccess.org/ Accessed November 21, 2025Weiner M., Gelfond J., Johnson-Pais T.L., Engle M., Peloquin C.A., Johnson J.L., Sizemore E.E., Mac Kenzie W.R. Elevated plasma moxifloxacin concentrations and SLCO1B1 g.-11187G>A polymorphism in adults with pulmonary tuberculosis // Antimicrobial Agents and Chemotherapy. – 2018. – Vol. 62, № 5. – Р. e01802 01817.Weiner M., Gelfond J., Johnson-Pais T.L., Engle M., Peloquin C.A., Johnson J.L., Sizemore E.E., Mac Kenzie W.R. Elevated plasma moxifloxacin concentrations and SLCO1B1 g.-11187G>A polymorphism in adults with pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, vol. 62, no. 5, pp. e01802 01817.WHO. Global Tuberculosis Report 2024. – Geneva: World Health Organization. – 2024. – P. 1-68. Available at: https://worldhealthorg.shinyapps.io/tb_profiles/ [Accessed 21.10.2025]WHO, Global Tuberculosis Report 2024. Geneva, World Health Organization. 2024, pp. 1-68. Available: https://worldhealthorg.shinyapps.io/tb_profiles/ Accessed October 21, 2025Yang S., Hwang S.J., Park J.Y., Chung E.K., Lee J.I. Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis // BMJ Open. – 2019. – Vol. 9, № 8. – Р. e027940. https://doi.org/10.1136/bmjopen-2018-027940Yang S., Hwang S.J., Park J.Y., Chung E.K., Lee J.I. Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. BMJ Open, 2019, vol. 9, no. 8, pp. e027940. https://doi.org/ 0.1136/bmjopen-2018-027940Zhang M., Wang S., Wilffert B., Tong R., van Soolingen D., van den Hof S., Alffenaar J.W. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis // Br J Clin Pharmacol. – 2018. – Vol. 84, № 12. – Р. 2747-2760. https://doi.org/10.1111/bcp.13722Zhang M., Wang S., Wilffert B., Tong R., van Soolingen D., van den Hof S., Alffenaar J.W. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. Br. J. Clin. Pharmacol., 2018, vol. 84, no. 12, pp. 2747-2760. https://doi.org/10.1111/bcp.13722Zhang X.H., Xie Y., Xu Q.G., Cao K., Xu K., Jin Z.B., Li Y., Wei S.H. Mitochondrial mutations in ethambutol-induced optic neuropathy // Front Cell Dev Biol. – 2021. – № 9. – Р. 754676. https://doi.org/10.3389/fcell.2021.754676Zhang X.H., Xie Y., Xu Q.G., Cao K., Xu K., Jin Z.B., Li Y., Wei S.H. Mitochondrial mutations in ethambutol-induced optic neuropathy. Front. Cell Dev. Biol., 2021, no. 9, pp. 754676. https://doi.org/10.3389/fcell.2021.754676Zou J., Chen S., Rao W., Fu L, Zhang J., Liao Y., et al. Population pharmacokinetic modeling of bedaquiline among multidrug-resistant pulmonary tuberculosis patients from China // Antimicrob Agents Chemother. – 2022. – Vol. 66, №10. – Р. e0081122. https://doi.org/10.1128/aac.00811-22Zou J., Chen S., Rao W., Fu L, Zhang J., Liao Y. et al. Population pharmacokinetic modeling of bedaquiline among multidrug-resistant pulmonary tuberculosis patients from China. Antimicrob. Agents Chemother., 2022, vol. 66, no. 10, pp. e0081122. https://doi.org/10.1128/aac.00811-22

The authors declare that there are no conflicts of interest present.